In addition, this platform will help increase the visibility of ongoing clinical trials; and ultimately facilitate patient recruitment.
In addition to the regular eligibility criteria listed above, TiP abstracts must fulfill the following criteria:. After the submission deadline, all completed and eligible abstracts will be made available to the ASH Abstract Reviewers for blinded review and scoring, and final decisions will be made by mid-November Abstracts will be evaluated and scored solely on their scientific merits.
Note: Trials in Progress abstracts will be flagged, and reviewers will be provided additional guidance for reviewing them e. Incomplete abstracts will not be reviewed. The same study must not be submitted as multiple abstracts.
Abstracts that are simply different versions of a single study will be rejected. Abstracts will be peer reviewed according to the subject categories. Authors must indicate during online submission the appropriate review category one only.
Please use the list of abstract review categories, which provides detailed descriptions of each category, to assist you in selecting the correct abstract classification.
These categories have been updated; please read through all of the categories and select the category most closely associated with your abstract.
Requests to change a review category will not be accepted after the closing of submissions. Note: All oral and poster presentations whether you attend in person or virtually will need to be pre-recorded and submitted by November 17th. Recognizing that the results of some top-quality research may not be available by the general abstract submission deadline, the ASH Program Committee offers an option for late-breaking abstracts.
Disclosure includes relationships held by you or any individual with whom you directly share income. You must disclose the relationship type and the name of the ineligible company for each of the following areas in which you maintain a relationship.
Exact dollar amounts are not necessary. You will have the option to a note that there are no financial relationships to disclose or to b provide relationship information. Disclosed information may include the following areas:. You will be required to note whether your presentation will include discussion of off-label use of products. If so, please use the Off-Label Disclosure section of the abstract form to identify the product s and off-label use s.
During the disclosure submission process, you will also be required to indicate your compliance with the following statements, which include measures to ensure clinical content validity:. The abstract submission site is now open. All abstracts must be submitted by October 28, , at p.
Submissions that are incomplete by the deadline will be rejected. ASH supports several types of awards for high-scoring abstracts submitted by hematologists-in-training. How to be considered for an Abstract Achievement Award:. All hematologist-in-training authors must upload the required letter into the program in order to complete the abstract submission.
The deadline for receipt of the hematologist-in-training letter is therefore, August 3, There will be no exceptions. Completion of all required disclosure information in the online abstract submission system serves as an agreement and is accepted in lieu of a faxed signature. It certifies the ASH abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that:.
A sample abstract is provided for your reference below. Note that the title, authors, and institutions are entered in separate fields in the submission form, not in the abstract body, as they are not included in the character count. Canver, B. Martyn 4 , Laura J. Orkin, M. Such knowledge is essential to develop mechanism-based, targeted approaches to reactivate HbF production.
LRF-deficient adult erythroblasts showed significant induction of Hbb-bh1, but not Hbb-y. Notably, the HbF reactivation occurred without changes in levels of transcripts encoding known HbF repressors, including BCL11A, the principal known switching factor. The most enriched motif identified in either was concordant with that previously identified in vitro using CAST analysis Maeda et. Nature , confirming antibody specificity.
Send related correspondence and questions regarding abstract submissions or notifications to: ASHabstracts hematology. Any technical questions regarding navigation of the submission site itself should be directed to ash confex. Agenda for Nematology Research. About Us. Precision Medicine. Genome Editing and Gene Therapy. Immunologic Treatment.
Research Support and Funding. The late-breaking abstract submission site is now closed. Please note the following changes for Pre-recorded presentations for both oral and poster presentations are required by November 17th.
Poster presentations are minutes including a slide deck and graphic poster for in-person and virtual attendees. Traditional posters will be hung in the poster hall for those attending in-person, and the poster image will be provided on the virtual platform. Eligibility To submit an late-breaking abstract, the following criteria must be met: Late-breaking abstracts should highlight novel and substantive studies of high impact.
The late-breaking abstract deadline is not intended to be merely an extension of the general submission deadline and will focus on capturing abstracts with ground-breaking and novel data that otherwise could not be presented at the annual meeting. The selection process will be highly competitive; no more than six abstracts will be selected for an oral presentation in a late-breaking abstracts session on Tuesday morning of the ASH annual meeting. Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective clinical trial or the discovery of a mechanism underlying or characterizing a disease process such as the JAK2 mutation in myeloproliferative disorders , which were not fully available by the general abstract submission deadline.
Skip to main content. Register Sign In. Learn how to order a test if you already have an account or how to request an account that you can use to order tests. Submit critical notification contacts, and view policies and test lists for critical values, critical results, and semi-urgent results. Skip to main content. Register Sign In. If you feel that we have violated your copyrights, then please contact us immediately. You may send an email to arshadullahbangash gmail.
Comments Realy a great sugestion. Nice blog. I think this book is a truly amazing piece of art that everybody who is studying medical degrees should, at least, read it once.
I will be very pleased to have a chance to look at this book. Critical and Urgent Care contains four learning modules with a total available Topics are presented in a variety of learning formats beyond traditional book chapters.
The first learning module focuses on patients with stroke and the trauma and neurologic critical care patient population. The second module includes information on thrombosis and heparin management. The third module covers a range of topics including pain, agitation and delirium, smoke inhalation and toxic exposures, and endocrine emergencies.
The final module includes three new interactive features: 1 anticoagulation in unique patient populations; 2 anesthesia and mechanical ventilation; and 3 statistics in practice section on comparing three or more groups. The target audience for PSAP Book 2 Pulmonary and Gastroenterology is pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with pulmonary and gastroenterological disorders. Pulmonary and Gastroenterology contains four learning modules with a total available The first learning module includes information on asthma and chronic obstructive pulmonary disease management.
The second module focuses on a few pulmonary and gastroenterological infectious diseases, specifically pneumonia and intra-abdominal infections, including Clostridium difficile.
The third module covers gastroesophageal reflux disease and peptic ulcer disease. The final module includes three new interactive features: 1 tuberculosis; 2 inflammatory bowel disease; and 3 statistics in practice section on regression and correlation. Continuing education activities in PSAP cover the most recent published data past 3—5 years on a specific therapeutic area or patient-care problem.
For an additional fee, a one-color softbound print book can be added to these formats and shipped to your address. The target audience for PSAP Book 3 Hematology and Oncology is pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with hematologic and oncologic malignancies.
Hematology and Oncology contains five learning modules with a total available Buie, Pharm. The first learning module includes chapters focused on pharmacogenomics and oral chemotherapeutics.
The second module focuses on immunotherapies and the utilization of biosimilars. The third module focuses on updates in hematologic malignancies, specifically the acute leukemias and multiple myeloma.
The fourth module uses interactive cases to highlight updates in castration-resistant prostate cancer and the management of graft-versus-host disease in patients undergoing hematopoietic stem cell transplantation. The final module uses interactive cases to discuss recent updates in breast cancer. In addition, the final module includes part two a statistics feature focused on correlation and regression.
The target audience for PSAP Book 1 Infectious Diseases is pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with infectious diseases.
Infectious Diseases contains three learning modules with a total available Nix, Pharm. The first learning module includes chapters focused on new antimicrobial agents and dosing in special populations such as patients with obesity or those on renal replacement therapy. The second module focuses on difficult to treat infections including persistent Staphylococcus aureus bacteremia, selected antibacterial-resistant infections, and CMV infection in immunocompromised patients.
0コメント